Denali Therapeutics (DNLI) News Today $25.05 -3.40 (-11.95%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Denali Has A Neurodegenerative Edge Despite Market SkepticismNovember 16 at 9:08 AM | seekingalpha.comLos Angeles Capital Management LLC Decreases Position in Denali Therapeutics Inc. (NASDAQ:DNLI)Los Angeles Capital Management LLC decreased its holdings in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 47.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 27,940 shares oNovember 16 at 4:24 AM | marketbeat.comDenali Therapeutics (NASDAQ:DNLI) Trading Down 8.3% - Here's What HappenedDenali Therapeutics (NASDAQ:DNLI) Stock Price Down 8.3% - Time to Sell?November 15 at 4:14 PM | marketbeat.comState of New Jersey Common Pension Fund D Decreases Position in Denali Therapeutics Inc. (NASDAQ:DNLI)State of New Jersey Common Pension Fund D decreased its stake in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 24.8% in the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 77,483 shares of the company's stock after selling 25,613 shares dNovember 15 at 3:43 AM | marketbeat.comOppenheimer Sticks to Their Buy Rating for Denali Therapeutics (DNLI)November 14 at 6:43 AM | markets.businessinsider.comInsider Selling: Denali Therapeutics Inc. (NASDAQ:DNLI) Director Sells 1,020 Shares of StockNovember 13, 2024 | insidertrades.comWedbush Reduces Earnings Estimates for Denali TherapeuticsNovember 13, 2024 | americanbankingnews.comBaillie Gifford & Co. Sells 417,709 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI)Baillie Gifford & Co. trimmed its position in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 3.0% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 13,345,887 shares of the cNovember 12, 2024 | marketbeat.comPrincipal Financial Group Inc. Increases Stock Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI)Principal Financial Group Inc. increased its position in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 13.8% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 1,238,476 shares of the company's stock after purchasing an additional 149,939 shares during thNovember 12, 2024 | marketbeat.comDenali Therapeutics (NASDAQ:DNLI) Reaches New 12-Month High - Still a Buy?Denali Therapeutics (NASDAQ:DNLI) Sets New 12-Month High - Time to Buy?November 11, 2024 | marketbeat.comDenali Therapeutics: Promising Pipeline and Strategic Advancements Justify Buy RatingNovember 11, 2024 | markets.businessinsider.comWhat is B. Riley's Estimate for DNLI Q1 Earnings?Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Equities research analysts at B. Riley issued their Q1 2025 earnings per share (EPS) estimates for Denali Therapeutics in a research note issued to investors on Friday, November 8th. B. Riley analyst M. Mamtani anticipates that the company wiNovember 11, 2024 | marketbeat.comHC Wainwright Issues Pessimistic Outlook for DNLI EarningsNovember 11, 2024 | americanbankingnews.comFY2024 Earnings Estimate for DNLI Issued By HC WainwrightDenali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Equities researchers at HC Wainwright decreased their FY2024 earnings per share estimates for shares of Denali Therapeutics in a research note issued to investors on Thursday, November 7th. HC Wainwright analyst A. Fein now forecasts that theNovember 11, 2024 | marketbeat.comWedbush Cuts Earnings Estimates for Denali TherapeuticsDenali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Research analysts at Wedbush cut their FY2024 earnings estimates for shares of Denali Therapeutics in a note issued to investors on Thursday, November 7th. Wedbush analyst L. Chico now anticipates that the company will post earnings of ($2.72November 11, 2024 | marketbeat.comDenali Therapeutics: Strategic Advancements and Financial Strength Justify Buy RatingNovember 8, 2024 | markets.businessinsider.comHC Wainwright Issues Pessimistic Estimate for DNLI EarningsDenali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Stock analysts at HC Wainwright lowered their FY2027 EPS estimates for shares of Denali Therapeutics in a report issued on Thursday, November 7th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings per share of $1November 8, 2024 | marketbeat.comDenali Therapeutics (DNLI) Receives a Hold from Stifel NicolausNovember 7, 2024 | markets.businessinsider.comMorgan Stanley Reaffirms Their Buy Rating on Denali Therapeutics (DNLI)November 7, 2024 | markets.businessinsider.comDenali Therapeutics (NASDAQ:DNLI) Posts Quarterly Earnings Results, Misses Expectations By $0.03 EPSDenali Therapeutics (NASDAQ:DNLI - Get Free Report) released its earnings results on Wednesday. The company reported ($0.63) EPS for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.03). During the same period in the previous year, the firm earned ($0.72) earnings per share.November 7, 2024 | marketbeat.comDenali Therapeutics' (DNLI) Buy Rating Reaffirmed at HC WainwrightHC Wainwright restated a "buy" rating and issued a $90.00 price target on shares of Denali Therapeutics in a report on Thursday.November 7, 2024 | marketbeat.comPromising Developments and Strategic Advancements Propel Denali Therapeutics’ Buy RatingNovember 7, 2024 | markets.businessinsider.comDenali Therapeutics Reports Third Quarter 2024 Financial Results and Business HighlightsNovember 6, 2024 | globenewswire.comabrdn plc Sells 209,356 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI)abrdn plc lowered its holdings in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 36.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 363,679 shares of the company's stock after selling 209November 2, 2024 | marketbeat.comDenali Therapeutics price target raised to $45 from $40 at JefferiesNovember 1, 2024 | markets.businessinsider.comJefferies Sticks to Their Buy Rating for Denali Therapeutics (DNLI)November 1, 2024 | markets.businessinsider.comDenali Therapeutics (NASDAQ:DNLI) Given New $45.00 Price Target at Jefferies Financial GroupJefferies Financial Group raised their price target on shares of Denali Therapeutics from $40.00 to $45.00 and gave the stock a "buy" rating in a research note on Friday.November 1, 2024 | marketbeat.comDenali Therapeutics Inc. (NASDAQ:DNLI) Receives Consensus Rating of "Moderate Buy" from AnalystsDenali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) has received an average recommendation of "Moderate Buy" from the ten analysts that are covering the stock, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and seven have given a buy ratingOctober 27, 2024 | marketbeat.comZacks Research Has Bearish Estimate for DNLI Q2 EarningsDenali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Stock analysts at Zacks Research lowered their Q2 2026 EPS estimates for Denali Therapeutics in a research report issued on Wednesday, October 23rd. Zacks Research analyst A. Chakraborty now expects that the company will earn ($0.75) per sharOctober 25, 2024 | marketbeat.comDenali Therapeutics Inc. (NASDAQ:DNLI) CEO Ryan J. Watts Sells 40,000 SharesOctober 23, 2024 | insidertrades.comInsider Selling: Denali Therapeutics Inc. (NASDAQ:DNLI) CEO Sells 40,000 Shares of StockDenali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) CEO Ryan J. Watts sold 40,000 shares of the stock in a transaction on Friday, October 18th. The stock was sold at an average price of $27.69, for a total value of $1,107,600.00. Following the transaction, the chief executive officer now owns 235,807 shares of the company's stock, valued at $6,529,495.83. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.October 22, 2024 | marketbeat.comDenali Therapeutics Inc. (DNLI): Jeff Bezos Is Buying This Stock NowOctober 14, 2024 | msn.comDenali Therapeutics (NASDAQ:DNLI) Stock Price Down 3.8% on Analyst DowngradeDenali Therapeutics (NASDAQ:DNLI) Stock Price Down 3.8% Following Analyst DowngradeOctober 14, 2024 | marketbeat.comDenali Therapeutics Inc. (NASDAQ:DNLI) Short Interest UpdateDenali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) was the recipient of a significant decline in short interest in September. As of September 30th, there was short interest totalling 7,740,000 shares, a decline of 17.7% from the September 15th total of 9,400,000 shares. Based on an average daily volume of 961,300 shares, the short-interest ratio is presently 8.1 days. Currently, 6.5% of the company's stock are short sold.October 13, 2024 | marketbeat.comDenali Therapeutics (DNLI) Receives a Buy from TD CowenOctober 12, 2024 | markets.businessinsider.comDenali Therapeutics (NASDAQ:DNLI) Trading Up 6.4% - Still a Buy?Denali Therapeutics (NASDAQ:DNLI) Trading 6.4% Higher - Here's What HappenedOctober 11, 2024 | marketbeat.comDenali Therapeutics (NASDAQ:DNLI) Price Target Lowered to $28.00 at JPMorgan Chase & Co.JPMorgan Chase & Co. cut their price target on shares of Denali Therapeutics from $29.00 to $28.00 and set an "overweight" rating on the stock in a report on Friday.October 11, 2024 | marketbeat.comDenali Therapeutics Stock Is Sliding After The Bell: Here's WhyOctober 10, 2024 | msn.comThe Manufacturers Life Insurance Company Raises Stake in Denali Therapeutics Inc. (NASDAQ:DNLI)The Manufacturers Life Insurance Company boosted its stake in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 15.5% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 172,281 shares of the company's stock after purchasing an additionalOctober 8, 2024 | marketbeat.comDenali Therapeutics (NASDAQ:DNLI) Rating Lowered to Neutral at Cantor FitzgeraldCantor Fitzgerald downgraded Denali Therapeutics from an "overweight" rating to a "neutral" rating in a report on Monday.October 7, 2024 | marketbeat.comAlgert Global LLC Lowers Stake in Denali Therapeutics Inc. (NASDAQ:DNLI)Algert Global LLC cut its stake in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 67.5% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 26,655 shares of the company's stock after selling 55,345 shares during the period. Algert GloOctober 7, 2024 | marketbeat.comDenali Therapeutics Inc. (NASDAQ:DNLI) Director Sells $870,900.00 in StockOctober 3, 2024 | insidertrades.comDenali Therapeutics Inc. (NASDAQ:DNLI) Stock Holdings Lifted by Squarepoint Ops LLCSquarepoint Ops LLC raised its position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 90.6% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 123,680 shares of the company's stocOctober 3, 2024 | marketbeat.comSteve E. Krognes Sells 30,000 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) StockDenali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) Director Steve E. Krognes sold 30,000 shares of the stock in a transaction dated Monday, September 30th. The stock was sold at an average price of $29.03, for a total transaction of $870,900.00. Following the transaction, the director now directly owns 29,096 shares in the company, valued at approximately $844,656.88. The transaction was disclosed in a filing with the SEC, which is available through this link.October 2, 2024 | marketbeat.comDenali Therapeutics Inc. (NASDAQ:DNLI) Stock Holdings Lifted by Dimensional Fund Advisors LPDimensional Fund Advisors LP lifted its position in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 6.3% in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,417,472 shares of the company's stock after acquiring an additionOctober 2, 2024 | marketbeat.comDenali Therapeutics Inc. (NASDAQ:DNLI) Given Average Rating of "Moderate Buy" by BrokeragesShares of Denali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) have received a consensus rating of "Moderate Buy" from the nine analysts that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the companOctober 2, 2024 | marketbeat.comDenali Therapeutics Inc. (NASDAQ:DNLI) Shares Bought by Thrivent Financial for LutheransThrivent Financial for Lutherans lifted its position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 101.5% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 130,September 30, 2024 | marketbeat.comDNLI Denali Therapeutics Inc.September 28, 2024 | seekingalpha.comFred Alger Management LLC Makes New $627,000 Investment in Denali Therapeutics Inc. (NASDAQ:DNLI)Fred Alger Management LLC bought a new position in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor bought 27,014 shares of the company's stock, valued at approximately $627,000. Several otherSeptember 28, 2024 | marketbeat.comPoint72 Asset Management L.P. Takes $24.45 Million Position in Denali Therapeutics Inc. (NASDAQ:DNLI)Point72 Asset Management L.P. purchased a new position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,053,150 sharesSeptember 27, 2024 | marketbeat.com Get Denali Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DNLI and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners (Ad)Trump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics… Get Your Free Gold Guide DNLI Media Mentions By Week DNLI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DNLI News Sentiment▼0.260.55▲Average Medical News Sentiment DNLI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DNLI Articles This Week▼284▲DNLI Articles Average Week Get Denali Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DNLI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Cytokinetics News Today Prothena News Today REGENXBIO News Today BioMarin Pharmaceutical News Today Vaxcyte News Today Neurocrine Biosciences News Today Bio-Techne News Today Exelixis News Today Revolution Medicines News Today Qiagen News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:DNLI) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Denali Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Denali Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DNLI Stock Alerts